Single gene mutations and prognosis in limited‐stage follicular lymphoma treated with radiation therapy-Reference-Cited by-同舟云学术

Single gene mutations and prognosis in limited‐stage follicular lymphoma treated with radiation therapy

Published:2024-08-07 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Hershenfeld Samantha A.¹^ORCID,Tobin Josuha W.D.²³^ORCID,Shelton Victoria¹,Calvente Lourdes¹,Lajkosz Katherine¹,Liu Ting¹,Brodtkorb Marianne⁴,d'Amore Francesco Annibale⁵,Ludvigsen Maja⁵⁶^ORCID,Baetz Tara⁷,LeBrun David⁸,Johnson Nathalie⁹,Crump Michael¹^ORCID,Hong Michael¹,Kuruvilla John¹^ORCID,Tremblay‐LeMay Rosemarie¹,MacManus Michael¹⁰,Tsang Richard¹,Hodgson David C.¹^ORCID,Gandhi Maher K.²³,Kridel Robert¹^ORCID

Affiliation:

1. Princess Margaret Cancer Center University Health Network Toronto Ontario Canada

2. Mater Research University of Queensland Brisbane Queensland Australia

3. Department of Haematology Princess Alexandra Hospital Brisbane Queensland Australia

4. Department of Oncology Oslo University Hospital Oslo Norway

5. Department of Hematology Aarhus University Hospital Aarhus Denmark

6. Department of Clinical Medicine Aarhus University Aarhus Denmark

7. Queen's University Kingston Ontario Canada

8. Department of Pathology and Molecular Medicine Queen's University Kingston Ontario Canada

9. Departments of Medicine and Oncology Jewish General Hospital Montreal Quebec Canada

10. Peter MacCallum Cancer Centre Melbourne Victoria Australia

Abstract

SummaryRadiotherapy is routinely used for management of limited‐stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69‐gene panel in 117 limited‐stage FL patients treated with radiotherapy and identified recurrently mutated genes. CREBBP was most frequently mutated, and mutated CREBBP was associated with inferior progression‐free survival, though not after false discovery rate adjustment. This association failed to validate in an independent cohort. We conclude that recurrent gene mutations do not predict outcomes in this setting. Alternative biomarkers may offer better prognostic insight.

Funder

Leukemia and Lymphoma Society of Canada

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19698

Reference22 articles.

1. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board

3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B‐Cell Lymphomas V.5.2022. © National Comprehensive Cancer Network Inc. 2022. All rights reserved. Accessed [November 1 2023]. To view the most recent and complete version of the guideline go online to NCCN.org.

4. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG

5. Long-term outcomes for patients with limited stage follicular lymphoma